InhalPlus is developing a technology that enables medication to be administered via the airways during artificially supported breathing.
InhalPlus has raised €500k across 1 funding round from 1 investor, most recently a Pre-Seed round in Oct 2026. Based in Hanover, Germany; active in Healthtech. Data as of 27 Oct 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-26 | Pre-Seed | €500k |
| NBank Capital |
| View deal → |
Global coverage: FundingData
